Cantor Fitzgerald analyst Rick Bienkowski initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Overweight rating and announces Price Target of $62.
BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023
First Patient Dosing in BEAM-201 Trial in Patients with
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.
Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close at $114.92 on Friday.
BMO Capital analyst Kostas Biliouris upgrades Beam Therapeutics (NASDAQ:BEAM) from Market Perform to Outperform and raises the price target from $61 to $66.